Norris Medicines Ltd (524414) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524414 | NSE: | Pharmaceuticals & Drugs | Small Cap

Norris Medicines Share Price

15.24 0.57 3.89%
as on 05-Dec'25 12:10

Norris Medicines Ltd (524414) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524414 | NSE: | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Norris Medicines

Based on:

M-Cap below 100cr DeciZen not available

Norris Medicines stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
14.7 Cr.
52-wk low:
14
52-wk high:
24.7

Is Norris Medicines Ltd an attractive stock to invest in?

1. Is Norris Medicines Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Norris Medicines Ltd is a below average quality company.

2. Is Norris Medicines Ltd undervalued or overvalued?

The key valuation ratios of Norris Medicines Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

3. Is Norris Medicines Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Norris Medicines Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Norris Medicines:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Norris Medicines Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 4.1%-4.1%-17%-9.2%-18.6%-17.9%-6.6%3.2%-8.6%-10.1%-
Value Creation
Index
-0.7-1.3-2.2-1.7NANANANANANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 18.920.513.616.37.812.39.48.45.65.87
Sales YoY Gr.-8.5%-33.7%19.9%-51.8%56.3%-22.9%-11.4%-32.5%3.2%-
Adj EPS -0-0.7-2.5-1.7-2.8-5-3.3-1.8-1.2-1.2-1.5
YoY Gr.-NANANANANANANANANA-
BVPS (₹) 5.44.62.10.4-2.5-7.5-10.8-12.5-13.7-15-15.8
Adj Net
Profit
-0-0.7-2.5-1.7-2.8-5-3.3-1.8-1.2-1.2-2
Cash Flow from Ops. 1.4-10.8-1.9-2.91.1-11.20.20.5-
Debt/CF from Ops. 5.6-11.714.2-7.4-6.216.5-20.917.8126.842.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -12.3%-5.8%-14.9%3.2%
Adj EPS NANANANA
BVPS-212.1%NANANA
Share Price - 22.4% 3.3% -34.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-0.2-14.9-76.5-138.4271.2100.236.115.198.710
Op. Profit
Mgn %
4.40-14.1-3.8-27.5-14.2-0.811.1-2.9-4.5-7.5
Net Profit
Mgn %
-0.1-3.6-18.6-10.3-36.2-40.5-34.6-20.9-20.8-21.3-21.2
Debt to
Equity
1.42.55.538.2-7.3-2.5-2-1.7-1.6-1.5-
Working Cap
Days
159164254194396268288254438470123
Cash Conv.
Cycle
6773106591979969107218217-84

Recent Performance Summary

Sales growth is good in last 4 quarters at 78.40%

Return on Equity has declined versus last 3 years average to 10.00%

Sales growth has been subdued in last 3 years -14.89%

Latest Financials - Norris Medicines Ltd.

Standalone Consolidated
TTM EPS (₹) -1.5 -
TTM Sales (₹ Cr.) 7.3 -
BVPS (₹.) -15.8 -
Reserves (₹ Cr.) -26 -
P/BV -0.93 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 14.00 / 24.65
All Time Low / High (₹) 0.60 / 36.75
Market Cap (₹ Cr.) 14.7
Equity (₹ Cr.) 10
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Norris Medicines:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Norris Medicines - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Norris Medicines

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales18.8620.4613.5716.277.8412.259.448.365.645.82
Operating Expenses 18.0220.5315.4916.8810149.517.445.826.08
Manufacturing Costs2.773.385.925.953.981.341.091.270.950.81
Material Costs9.3010.403.436.382.238.745.613.362.663.45
Employee Cost 4.845.314.933.813.233.102.332.301.821.41
Other Costs 1.121.441.200.740.560.810.490.500.390.42
Operating Profit 0.83-0.08-1.92-0.61-2.16-1.74-0.070.92-0.18-0.26
Operating Profit Margin (%) 4.4%-0.4%-14.1%-3.8%-27.5%-14.2%-0.8%11.0%-3.3%-4.5%
Other Income 0.300.140.140.040.090.050.030.010.030.06
Interest 0.670.600.700.730.881.631.481.500.370.44
Depreciation 0.600.650.710.710.730.670.660.630.570.54
Exceptional Items 0000000000
Profit Before Tax -0.14-1.18-3.18-2.01-3.68-3.99-2.18-1.19-1.10-1.18
Tax -0.18-0.42-0.67-0.33-0.840.971.080.560.090.06
Profit After Tax 0.04-0.77-2.51-1.68-2.84-4.96-3.26-1.75-1.19-1.24
PAT Margin (%) 0.2%-3.8%-18.5%-10.3%-36.2%-40.5%-34.6%-20.9%-21.1%-21.3%
Adjusted EPS (₹)0.0-0.8-2.5-1.7-2.9-5.0-3.3-1.8-1.2-1.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 5.334.562.050.37-2.47-7.43-10.69-12.44-13.63-14.87
Share Capital 9.939.939.939.939.939.939.939.939.939.93
Reserves -4.60-5.36-7.88-9.55-12.39-17.36-20.62-22.37-23.56-24.79
Minority Interest0000000000
Debt7.5111.2811.2614.2017.9218.3921.0821.4021.5221.58
Long Term Debt7.497.577.7111.2414.9815.5218.1018.4318.5918.53
Short Term Debt0.023.713.552.962.942.862.982.982.933.05
Trade Payables2.543.574.733.902.895.241.331.381.782.57
Others Liabilities 1.130.820.17-0.90-1.440.900.872.293.553.62
Total Liabilities 16.5120.2318.2017.5716.9017.1012.5812.6313.2212.91

Fixed Assets

Gross Block25.6327.8527.4127.7027.7827.8727.9227.9527.7427.76
Accumulated Depreciation17.2917.8818.0918.8019.5320.2020.8521.4821.9622.49
Net Fixed Assets 8.349.979.328.908.257.677.076.475.795.27
CWIP 0000000000
Investments 0.010.010.010.010.010.010.010.010.010.01
Inventories3.423.694.473.764.015.102.423.204.334.13
Trade Receivables2.774.722.473.012.761.791.091.101.061.41
Cash Equivalents -0.110.050.100.080.060.020.020.020.040.04
Others Assets 2.081.791.831.801.812.511.971.8422.05
Total Assets 16.5120.2318.2017.5716.9017.1012.5812.6313.2212.91

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 1.35-0.960.80-1.92-2.881.11-1.011.200.170.51
PBT 0.04-1.18-3.18-2.01-3.68-3.99-2.18-1.19-1.10-1.18
Adjustment 1.051.191.381.421.592.292.132.120.950.96
Changes in Working Capital 0.26-0.972.6-1.33-0.792.82-0.950.270.320.73
Tax Paid 0000000000
Cash Flow From Investing Activity -0.34-2.05-0.08-0.290-0.06-0.09-0.020.05-0
Capex -0.32-2.28-0.06-0.29-0.08-0.09-0.06-0.030.09-0.02
Net Investments 000000000-0
Others -0.010.23-0.0200.080.03-0.030.01-0.040.02
Cash Flow From Financing Activity -1.323.16-0.662.182.86-1.091.10-1.18-0.20-0.50
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 00003.7400000
Interest Paid -0.67-0.60-0.70-0.73-0.88-1.63-1.48-1.50-0.37-0.44
Dividend Paid 0000000000
Others -0.653.760.042.9100.542.580.320.17-0.06
Net Cash Flow -0.310.150.06-0.02-0.02-0.04-000.020

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)0.71-15.52-76.01-138.44N/AN/AN/AN/AN/AN/A
ROCE (%)4.06-4.06-17.04-9.18N/AN/AN/AN/AN/AN/A
Asset Turnover Ratio1.131.120.710.910.460.720.640.660.440.45
PAT to CFO Conversion(x)33.75N/AN/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days636796611336856487077
Inventory Days576310992179136145123244265
Payable Days105107441247556170214147217230

Norris Medicines Ltd Stock News

Norris Medicines Ltd FAQs

The current trading price of Norris Medicines on 05-Dec-2025 12:10 is ₹15.24.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Norris Medicines stood at ₹14.67.
The latest P/E ratio of Norris Medicines as of 04-Dec-2025 is 0.00.
The latest P/B ratio of Norris Medicines as of 04-Dec-2025 is -0.93.
The 52-week high of Norris Medicines is ₹24.65 and the 52-week low is ₹14.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Norris Medicines is ₹7.28 ( Cr.) .

About Norris Medicines Ltd

No data to display
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×